Texas Permanent School Fund decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,427,434 shares of the biopharmaceutical company’s stock after selling 110,658 shares during the quarter. Pfizer makes up about 0.7% of Texas Permanent School Fund’s holdings, making the stock its 19th biggest position. Texas Permanent School Fund’s holdings in Pfizer were worth $51,787,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in PFE. Amundi Pioneer Asset Management Inc. grew its stake in Pfizer by 81.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock valued at $691,583,000 after buying an additional 8,563,358 shares during the last quarter. BlackRock Inc. grew its stake in Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after buying an additional 6,785,335 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Pfizer by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock valued at $1,674,223,000 after buying an additional 4,998,981 shares during the last quarter. Jensen Investment Management Inc. acquired a new position in Pfizer in the 2nd quarter valued at $110,291,000. Finally, Robeco Institutional Asset Management B.V. grew its stake in Pfizer by 75.3% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 7,038,854 shares of the biopharmaceutical company’s stock valued at $249,807,000 after buying an additional 3,024,270 shares during the last quarter. Institutional investors own 68.95% of the company’s stock.
In related news, VP Loretta V. Cangialosi sold 26,814 shares of Pfizer stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the completion of the transaction, the vice president now directly owns 102,360 shares of the company’s stock, valued at approximately $4,110,777.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at $2,979,552. The disclosure for this sale can be found here. Insiders have sold a total of 761,230 shares of company stock valued at $29,054,690 over the last ninety days. 0.06% of the stock is owned by insiders.
Shares of NYSE:PFE traded up $0.97 during midday trading on Friday, reaching $43.78. 28,490,527 shares of the company’s stock were exchanged, compared to its average volume of 21,858,029. The company has a market capitalization of $262.34 billion, a price-to-earnings ratio of 16.52, a PEG ratio of 2.23 and a beta of 0.96. Pfizer Inc. has a 12 month low of $33.20 and a 12 month high of $45.81. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. The company had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $0.67 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.11%. The ex-dividend date is Thursday, November 8th. Pfizer’s payout ratio is 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.